Purple Biotech (PPBT) Shares Outstanding (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Shares Outstanding (Entity) of $960.1 million for Q4 2025, up 585484.48% year-over-year from N/an in Q4 2024, and up 953.86% quarter-over-quarter from $91.1 million in Q3 2025.
Purple Biotech (PPBT) Shares Outstanding (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Shares Outstanding (Entity) for 12 consecutive years, with $960.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 585484.48% year-over-year to $960.1 million; the TTM figure through Dec 2025 stood at $960.1 million (up 585484.48% YoY), while the FY2025 annual figure was $960.1 million, up 585484.48% from the prior year.
- Shares Outstanding (Entity) grew to $960.1 million in Q4 2025 per PPBT's latest filing, from $91.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $960.1 million in Q4 2025 and bottomed at $87271.0 in Q2 2021.
- Historically, Shares Outstanding (Entity) has averaged $106.2 million across 5 years, with a median of $163957.0 in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 2.92% — and 2025, when it soared 585484.48%.
- Purple Biotech's Shares Outstanding (Entity) stood at $87840.0 in 2021, then climbed by 2.92% to $90405.0 in 2022, then advanced by 22.41% to $110666.0 in 2023, then surged by 48.15% to $163957.0 in 2024, then jumped by 585484.48% to $960.1 million in 2025.
- Business Quant data shows PPBT's Shares Outstanding (Entity) at $960.1 million in Q4 2025, $91.1 million in Q3 2025, and $54.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 81.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 960.11 Mn |
| Dec 31, 2025 | 960.11 Mn |
| Sep 30, 2025 | 91.10 Mn |
| Jun 30, 2025 | 54.72 Mn |
| Mar 31, 2025 | 163,957.00 |
| Dec 31, 2024 | 163,957.00 |
| Sep 30, 2024 | 34.65 Mn |
| Jun 30, 2024 | 27.53 Mn |
| Mar 31, 2024 | 110,666.00 |
| Dec 31, 2023 | 110,666.00 |
| Sep 30, 2023 | 90,405.00 |
| Jun 30, 2023 | 90,405.00 |
| Mar 31, 2023 | 90,405.00 |
| Dec 31, 2022 | 90,405.00 |
| Sep 30, 2022 | 87,840.00 |
| Jun 30, 2022 | 87,840.00 |
| Mar 31, 2022 | 87,840.00 |
| Dec 31, 2021 | 87,840.00 |
| Sep 30, 2021 | 87,561.00 |
| Jun 30, 2021 | 87,271.00 |